Please log in to determine if you are eligible to purchase PT Programs.
PLASMA CELL MYELOMA MRD - FL9
FL9
Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

Procedure Challenges per Shipment Number of Shipments
Plasma cell myeloma measurable (minimal) residual disease 3 Two shipments per year

  • Program FL9 is intended for laboratories that perform measurable (minimal) residual disease (MRD) testing (rare event analysis) for plasma cell myeloma.
  • Participation in this program alone does not satisfy PT requirements for laboratories performing more general analysis of leukemia/lymphoma specimens.


    Program Information

    • Two 4.5‑mL specimens containing a cell line/whole blood mixture simulating plasma cell myeloma measurable (minimal) residual desease with clinical history and pertinent laboratory data
    • One online case with clinical history and gated dot plots

    This program has stability of two days or less. The CAP cannot guarantee performance or offer credits for orders placed for shipment outside of the US and Canada.

    Shipping Schedule

    • Shipment A: May 22
    • Shipment B: December 4






  • Customers Who Bought This Item Also Bought
    Color Atlas of Flow Cytometry
    VIEW DETAILS >
    B-ALL MEASURABLE (MINIMAL) RESIDUAL DISEASE
    VIEW DETAILS >
    FLOW IMMUNOPHEN LEUKEMIA/LYMPHOMA
    VIEW DETAILS >
    MATURE B-CELL LEUKEMIA/LYMPHOMA MRD
    VIEW DETAILS >